Trial Profile
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary) ; Niacin
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 06 Oct 2015 Treatment table revised with an inclusion of extra placebo arm.
- 27 Aug 2015 New trial record